Rafaèle TordjmanFounder and CEO at Jeito Capital
Physician and researcher in hemato-oncology, Rafaèle Tordjman, MD PhD, has been an investor in life sciences since 2001In 2018, Rafaèle Tordjman created Jeito Capital, an independent investment company dedicated to the development of biopharma/biotech, for which she announced the closing of JEITO I at €200 with renowned institutional investors
JEITO’s mission is to finance and accelerate the development and time to market of life-changing innovations in therapeutic areas with high medical needs.
Previously, Rafaèle Tordjman worked at venture capital firm Sofinnova Partners for 16 years. She started as an analyst in 2001 and became Managing Partner and co-leader until 2017. With €1.5 billion assets under management, Rafaèle invested and sat on the Board of DBV Technologies [DBV], Ascendis [ASND], Lysogene [LYS], MedDay, Enyo Pharma, Flexion Therapeutics [FLXN], Preglem, before the company was sold to Gedeon Richter, Corevalve before it was sold to Medtronic, and Endoart, before it was sold to Allergan. She invested and is still at the board of Nucana Biomed [NCNA] and ObsEva [OBSV].
Driven by the idea of promoting women's entrepreneurship in healthcare, Rafaèle founded the association W.I.T.H (Women Innovating Together in Healthcare) in 2010, and brings together more than 500 talented women from around the world who arose from medical innovation throughout the whole value chain.
She was awarded Chevalier de la Légion d’Honneur in September 2020.